Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M918Revenue (TTM) $M6.0Net Margin (%)-893.6Altman Z-Score3.6
Enterprise Value $M793EPS (TTM) $-0.4Operating Margin %-894.2Piotroski F-Score4
P/E(ttm)--Beneish M-Score1.6Pre-tax Margin (%)-893.6Higher ROA y-yY
Price/Book11.810-y EBITDA Growth Rate %-4.5Quick Ratio8.1Cash flow > EarningsY
Price/Sales1515-y EBITDA Growth Rate %-0.1Current Ratio8.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-37.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-55.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M132ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ZIOP

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ZIOPJoel Greenblatt 2016-03-31 Reduce$4.89 - $9.59
($6.81)
$ 6.962%Reduce -12.49%96,406
ZIOPJoel Greenblatt 2015-12-31 Buy 0.01%$8.07 - $14.57
($11.04)
$ 6.96-37%New holding110,163
ZIOPJoel Greenblatt 2015-06-30 Sold Out -0.01%$8.81 - $12.5
($10.36)
$ 6.96-33%Sold Out0
ZIOPJoel Greenblatt 2015-03-31 Buy 0.01%$4.96 - $14
($9.88)
$ 6.96-30%New holding109,080
ZIOPFirst Eagle Investment 2013-06-30 Sold Out -0.0012%$1.52 - $2.62
($1.86)
$ 6.96274%Sold Out0
ZIOPFirst Eagle Investment 2013-03-31 Buy $1.72 - $5.71
($4.42)
$ 6.9657%New holding200,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ZIOP is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ZIOP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BELBEL CAESAR JCOO, CLO, and Secretary 2015-11-19Sell153,333$12.84-45.79view
LEBEL FRANCOISExecutive Vice President R&D 2015-06-09Sell50,000$10.12-31.23view
BRENNAN MURRAYDirector 2015-06-04Sell40,000$9.7-28.25view
Lafond Kevin GVice Pres., Treasurer, & CAO 2015-06-03Sell57,500$9.65-27.88view
KIRK RANDAL JDirector, 10% Owner 2015-02-09Buy1,440,000$8.75-20.46view
KIRK RANDAL JDirector, 10% Owner 2013-10-29Buy2,857,143$3.598.86view
KIRK RANDAL JDirector, 10% Owner 2012-01-20Buy1,923,075$5.233.85view
KIRK RANDAL JDirector, 10% Owner 2011-08-23Buy38,294$4.9939.48view
KIRK RANDAL JDirector, 10% Owner 2011-08-22Buy461,646$4.9241.46view
Fowler WycheDirector 2011-08-10Buy5,000$5.1934.1view

Quarterly/Annual Reports about ZIOP:

News about ZIOP:

Articles On GuruFocus.com
Intrexon Corp is expanding his business Jun 25 2015 
Hayman Advisors Update - Second Quarter Sells and Company Results Aug 26 2013 
Bass’ New Buy – ZIOPHARM Oncology Inc. May 16 2013 
The Far-Off Four, 52-week Lows Held by Gurus May 11 2013 

More From Other Websites
Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation May 20 2016
8 Stocks on the Move After ASCO Cancer Abstracts May 19 2016
ETF’s with exposure to ZIOPHARM Oncology, Inc. : May 19, 2016 May 18 2016
ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy... May 18 2016
Biotech stocks on the move May 18 2016
ZIOPHARM ONCOLOGY INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 18 2016
ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy... May 18 2016
ZIOPHARM ONCOLOGY INC Financials May 18 2016
ZIOPHARM Oncology, Inc. :ZIOP-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
Ziopharm Oncology faces downside trade May 16 2016
XBI Dropped, Markets Fell Due to Retail Sector Concerns May 12 2016
Ziopharm reports 1Q loss May 10 2016
Ziopharm reports 1Q loss May 10 2016
ZIOPHARM ONCOLOGY INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 10 2016
ZIOPHARM Reports First-Quarter 2016 Financial Results and Provides Update on Recent Activities May 10 2016
ZIOPHARM Reports First-Quarter 2016 Financial Results and Provides Update on Recent Activities May 10 2016
ZIOPHARM ONCOLOGY INC Files SEC form 10-Q, Quarterly Report May 10 2016
CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail May 10 2016
​This CEO of a small Boston biotech earned more than the CEOs of Novartis, Roche May 06 2016
ZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bearish Manner : ZIOP-US : April 29,... Apr 29 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)